Please assess the completion status of the following clinical trial:

Trial Title: A Study of Modified Stem Cells in Stable Ischemic Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Documented history of one completed ischemic stroke in subcortical region of MCA or lenticulostriate artery with or without cortical involvement~* Between 6 and 60 months post-stroke, and having a motor neurological deficit~* No significant further improvement with physical therapy/rehabilitation~* Able and willing to undergo computed tomography (CT), magnetic resonance imaging (MRI), and positron-emission tomography (PET) scans of the head~Exclusion Criteria:~* History of more than 1 symptomatic stroke~* History of seizures~* History or presence of any other major neurological disease~* Myocardial infarction within prior 6 mos.~* Known presence of any malignancy except squamous or basal cell carcinoma of the skin~* Participation in any other investigational trial within 4 weeks of initial screening and within 7 weeks of study entry~* Contraindications to head CT, MRI, or PET~* Pregnant or lactating

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- SB623 Implant (2.5M) (Type: EXPERIMENTAL): 2.5 million SB623 cells
- SB623 Implant (5.0M) (Type: EXPERIMENTAL): 5 million SB623 cells
- SB623 Implant (10.0M) (Type: EXPERIMENTAL): 10 million SB623 cells

Based on this trial design, predict the completion outcome and termination type (if applicable).